Q4 2025 Financial Results Nykode Q4 2025 Report

‌4TH QUARTER2025

INTERIM REPORT

Nykode Therapeutics ASA | Gaustadalléen 21, N-0349 Oslo, Norway | W: nykode.com | Org.no. N-990 646 066 MVA

‌HIGHLIGHTS

Oslo, Norway, February 25, 2026 - Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced its unaudited financial results for the quarter ended December 31, 2025.

• Total revenue and other income of USD 0.0 million, compared to USD 6.9 million for the fourth quarter of 2024.

• Total operating expenses of USD 8.1 million, compared to USD 12.9 million for the fourth quarter of 2024.

• Net loss of USD 8.0 million, compared to a net loss of USD

  6.8 million for the fourth quarter of 2024.

• Strong cash position of USD 60.3 million as of December 31, 2025.

  Highlights for the fourth quarter 2025:

• Advanced preparation for the Abili-T trial: submitted protocol to UK and relevant EU regulators, and received UK regulatory authorization in December.

• Secured supply of pembrolizumab for the Abili-T trial.

• U.S. patent granted relating to the company's proprietary NeoSELECTTM platform used for the selection of neoantigens for VB10.NEO, strengthening our intellectual property portfolio.

• Presented new analyses from two clinical trials further validating NeoSELECT's ability to identify neoantigens that drive strong and durable immune responses.

• Presented new preclinical data indicating that the company's ASIT platform can modulate the humoral immune response, including after disease induction.

• Expanded into a new preclinical autoimmune indication, Vitiligo, demonstrating that Nykode's targeted approach is capable of reducing CD8+ disease-mediated T cell response.

  Highlights after December 31, 2025:

• Announced new interim data from the VB-C-03 trial in head and neck cancer, showing an objective response rate of 38.5%, a significant improvement of current standard of care of 19%. The results will be presented at an oral presentation at the International Congress on Innovative Approaches in Head & Neck Oncology (ICHNO) in March 2026.

‌KEY FINANCIAL FIGURES

4TH QUARTER TWELVE MONTHS ENDED

‌BUSINESS UPDATE

Nykode's strategy is focused on three core assets with the greatest potential to deliver significant clinical and commercial impact.

Abi-suva is prioritized as the lead value driver, with a focus on initiating a new randomized controlled trial, Abili-T, in HPV16-driven first-line recurrent/metastatic head and neck cancer (1L r/m HNSCC) designed to demonstrate clinical efficacy and support continued advancement of the asset.

Development of VB10.NEO is focused on strengthening its position as the most attractive unencumbered individualized neoantigen therapy through targeted investments, leveraging anticipated peer data readouts.

The tolerance platform is being further advanced with the aim to leverage Nykode's differentiated technology with best-in-class potential and pursuing partnerships to accelerate development.

Nykode maintains disciplined execution and financial focus to reach key inflection points within the estimated cash runway into 2028, further extending into 2029 based on a positive outcome in the pending tax case.

Abi-suva is an off-the-shelf therapeutic immunotherapy targeting HPV16+ induced malignancies, with head and neck cancer and cervical cancer as the primary indications, both representing areas of significant unmet medical need. The product candidate is wholly owned by Nykode.

The ongoing VB-C-03 trial is an open-label, dose-escalation Phase 1/2a study of abi-suva in combination with pembrolizumab (KEYTRUDA®1) for PD-L1- positive, first-line, non-resectable, recurrent or metastatic squamous cell head and neck cancer (NCT06016920) with doses up to 9 mg. The last patient is expected to receive the final abi-suva dose in May 2026. New interim data announced in February show an objective response rate of 38.5%, a significant improvement of current standard of care of 19%. The results will be presented at an oral presentation at the International Congress on Innovative Approaches in Head & Neck Oncology (ICHNO) in March 2026.

The Abili-T trial is a randomized, open-label, multicenter Phase 2 trial which will evaluate abi-suva in combination with MSD's (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy, pembrolizumab (KEYTRUDA®), versus pembrolizumab alone, as first-line treatment for human papilloma virus (HPV)16-positive, PD-L1-positive recurrent or metastatic head and neck squamous cell carcinoma (1L r/m HNSCC). The trial will enroll up to 100 patients and is powered to deliver robust efficacy data in combination with pembrolizumab, the current

standard of care for PD-L1-positive 1L r/m HNSCC. MSD will supply pembrolizumab for the Abili-T trial.

Preparations for the initiation of the Abili-T trial are proceeding according to plan. The protocol for the trial was submitted to the UK regulatory authorities in November and the relevant EU regulatory authorities in early December 2025. The application was subsequently approved by the UK authorities in late December. Based on early correspondence with EU regulatory authorities, an approval of the application is expected in the second quarter of 2026

Based on current timelines, Nykode expects the first patient dosed during the first half of 2026. Interim analyses for efficacy are planned throughout the trial, with the first interim analysis expected in 2027.

VB10.NEO is a clinically validated individualized neoantigen therapy (INT) with potential applicability across a broad spectrum of cancer indications.

In November 2025, Nykode was granted a U.S. patent (no. 12,462,898) titled "Method For Selecting Neoepitopes," which relates to the company's proprietary NeoSELECTTM platform used for the selection of neoantigens for VB10.NEO. The patent strengthens Nykode's intellectual property position on selecting the right targets for the therapy, which is one of the

1 KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

key elements of designing the most effective INT. The patent is valid until September 2039.

At the Society for Immunotherapy of Cancer (SITC) 2025 annual meeting in November, Nykode presented new data from two clinical trials that further validate the ability of Nykode's proprietary NeoSELECTTM platform to identify neoantigens that drive strong and durable immune responses. VB10.NEO induced neoantigen-specific T cell responses in 94% and 100% of participants in the VB N-01 and VB N-02 trials, respectively. Further, survival analyses from the VB N-01 trial showed that high-quality, immunogenic neoantigens prioritized by NeoSELECTTM were associated with favorable overall survival in a heterogeneous, heavily pre-treated patient population.

At the NextGen Biomed conference in March 2026, Nykode will further showcase the VB10.NEO platform. With its established supply chain, proprietary AI-powered epitope selection algorithm and strong durable clinical immune response achieved across two clinical trials. VB10.NEO is well positioned to leverage on peer data readouts expected within the next 15 months.

Autoimmune disorders are caused by unwanted immune responses to self-antigens. Antigen-specific immune tolerance (ASIT) can suppress autoimmunity without compromising normal immune function. This approach also has potential applications in treating allergies and preventing organ transplant rejection. Recent advancements support the best-in-class potential of Nykode's proprietary APC-targeting platform, specifically in reducing unwanted,

disease-causing immune responses with long, durable reversion of disease symptoms and with efficacy proven to be dependent on APC-targeting. Nykode will further substantiate the platform's potential and explore partnerships to advance development and diversify indications.

At the Protein & Antibody Engineering Summit (PEGS) in November, Nykode showcased novel data demonstrating that it's APC-targeted vaccine candidates reduced antigen-specific IgG auto-antibody production in the EAE pre-clinical model, even when administered after disease induction. This ability to effectively modulate also the humoral component of the immune response underscores the potential of Nykode's APC-targeted vaccine candidate's for advancing autoimmune disease therapies.

Nykode is further expanding the range of autoimmune disease models where the APC-targeting ASIT platform is capable of modulating the immune response. In a preclinical vitiligo model, data demonstrated the ability to reduce a TRP2-specific CD8+ disease-mediated T cell response.

At the Keystone Symposia: Autoimmunity & Autoinflammation in January 2026, Nykode presented further insight into the translatability of its ASIT platform where various targeted therapies binds human APCs at low nM range with ability to modulate the specific immune response.

Overall, these findings demonstrate that Nykode's APC-targeted immune tolerance therapy can act through multiple arms of the antigen-specific immune system and create durable responses in several therapeutic areas. Accordingly, Nykode is actively extending its exploratory efforts in other preclinical models and continuing its pioneering work using AI for antigen selection and optimal product design to further showcase a strong and diverse technology that can be applied for various autoimmune disorders.

In March 2026, Nykode will present data and further progress on the APC-targeted ASIT platform's ability to precisely re-establish antigen-specific immune tolerance through selective antigen delivery to APCs at both the 9th Antigen-Specific Immune Tolerance Summit (ASIT) in Boston and at NextGen Biomed in London.

Nykode has received a letter from the Norwegian Tax Administration (Norw: Skatteklagenemda) stating that we can expect an outcome of the appeal under the pending tax case in the first half of 2026.

Nykode continues discussions with Regeneron regarding the future of the collaboration programs, and these programs are no longer included in Nykode's strategy or financial forecasts.

‌FINANCIAL REVIEW

(Numbers in brackets are for the corresponding period the previous year unless otherwise specified)

The fourth quarter of 2025 showed a net loss of USD 8.0 million compared to a net loss of USD 6.8 million for the same period in 2024.

Total revenue and other income amounted to USD 0.0 million, compared to USD 6.9 million for the same period in 2024. Revenue from contracts with customers was USD 0.0 million (USD 6.8 million). The decrease is mainly due to the termination of the Genentech agreement in the fourth quarter of 2024.

Total operating expenses amounted to USD 8.1 million, compared to USD 12.9 million for the same period in 2024. Employee benefit expenses were USD 3.9 million in the fourth quarter of 2025 (USD 8.3 million). The decrease in employee benefit expenses is mainly due to fewer employees in the fourth quarter of 2025 compared to the same period in 2024 following an organizational restructuring. Other operating expenses decreased from USD 4.1 million in the fourth quarter of 2024 to USD 3.7 million in the fourth quarter of 2025. The decrease mainly reflects reduced clinical activities compared to previous year.

Net financial income and costs were positive USD 0.04 million in the fourth quarter of 2025 (USD 1.0 million negative).

Finance income and finance costs mainly relate to interest

income and movements in foreign currency exchange rates. The increase is mainly due to lower currency losses in the fourth quarter of 2025 compared to the same period in 2024, mainly caused by movements in the USD/NOK exchange rate relating to the cash balance held in NOK and the non-current receivable denominated in NOK.

The Group recognized tax income of USD 0.0 million in the fourth quarter of 2025 compared to a tax income of USD 0.2 million in the same period of 2024. The income tax expense is primarily related to movement in deferred tax and currency translation effects.

The net result for the year ended December 31, 2025 was a net loss of USD 12.2 million compared to a net loss of USD

38.8 million for the same period in 2024.

Total revenue and other income amounted to USD 0.5 million compared to USD 9.2 million for the same period in 2024.

Revenue from contracts with customers was USD 0.0 million (USD 8.7 million). The decrease is mainly due to the termination of the Genentech agreement in the fourth quarter of 2024. Other income was USD 0.5 million (USD 0.5 million) and relates to government grants.

Total operating expenses amounted to USD 29.0 million compared to USD 57.5 million for the same period in 2024. Employee benefit expenses were USD 13.6 million (USD 31.0

million). The decrease in employee benefit expenses is mainly due to the reduced number of employees. Other operating expenses decreased from USD 24.2 million in the year ended December 31, 2024 to USD 13.5 million in the year ended December 31, 2025. The decrease mainly reflects reduced clinical activities compared to previous year.

Net financial income and costs were positive USD 10.9 million in the year ended December 31, 2025 (USD 2.8 million positive). Finance income and finance costs mainly relate to interest income and movements in foreign currency exchange rates. The increase is primarily due to a net currency gain of USD 7.5 million in 2025, compared to a net loss of USD 4.0 million in 2024. The currency gain/loss is mainly caused by movements in the USD/NOK exchange rate relating to the cash balance held in NOK and the non-current receivable denominated in NOK.

The Group recognized tax income of USD 5.5 million compared to USD 6.7 million in the same period of 2024. The income tax expense is primarily related to movement in deferred tax and currency translation effects.

Cash and cash equivalents amounted to USD 60.3 million at December 31, 2025 compared to USD 115.4 million at

December 31, 2024.

Total equity amounted to USD 91.5 million at December 31, 2025, compared to USD 136.2 million at December 31, 2024. The decrease is mainly due to the net loss for the period of USD 12.2 million and the dividend of USD 32.3 million paid in the second quarter of 2025.

Other non-current receivables were USD 32.2 million (USD 28.6 million), which mainly reflects the NOK 325 million (USD 29 million) payment to the Norwegian Tax Authorities ("NTA") in the fourth quarter of 2023 following their negative

decision, where the NTA reiterated their position that the upfront payments received under a license agreement entered into in 2020 should be treated as taxable income in full in 2020, rather than the use of taxable gain/loss whereby part of the taxable income should be deferred to subsequent years. Nykode has appealed the decision to the Norwegian Tax Administration (Norw: Skatteklagenemda). The increase is due to movements in exchange rates.

Net change in cash and cash equivalents was negative USD

3.3 million in the fourth quarter of 2025 compared to negative USD 8.6 million for the same period in 2024.

Net cash flow from operating activities was negative USD 5.2 million in the fourth quarter of 2025 (USD 11.4 million negative), primarily driven by a reduction of contract liabilities related to the Genentech agreement in the fourth quarter of 2024 and an increase in trade and other payables in the fourth quarter of 2025, offset by a higher loss before tax in the fourth quarter in 2025 compared to the same period in 2024.

Net cash flow from investing activities was positive USD 2.1 million in the fourth quarter of 2025 (USD 3.2 million positive). The amounts mainly relate to interest received.

Net cash flow from financing activities was negative USD 0.3 million in the fourth quarter of 2025 (USD 0.5 million negative).

Net change in cash and cash equivalents was negative USD

59.5 million in the year ended December 31, 2025, compared to USD 45.7 million negative for the same period in 2024.

Net cash flow from operating activities was negative USD

29.5 million in the year ended December 31, 2025, compared to USD 51.2 million negative for the same period in 2024, primarily driven by reduced loss before tax in 2025 compared to the same period in 2024, offset by increased unrealized currency gain.

Net cash flow from investing activities was positive USD 3.5 million in the year ended December 31, 2025 (USD 6.9 million positive). The amounts mainly relate to interest received.

Net cash flow from financing activities was negative USD 33.6 million in the year ended December 31, 2025 (USD 1.4 million negative), primarily due to the USD 32.3 million dividend payment in June 2025.

‌OUTLOOK

Nykode's main priority is initiating the randomized controlled trial in HPV16-driven 1st-line recurrent/ metastatic head and neck cancer, designed to demonstrate clinical efficacy and support the continued advancement of abi-suva. We expect to dose the first patient during the first half of 2026. Interim efficacy analyses are planned throughout the trial, with the first interim analysis expected in 2027.

Interim data from the VB-C-03 trial will be presented at the 10th International Congress on Innovative Approaches in Head & Neck Oncology (ICHNO) in March, 2026.

With an established supply chain, an in-house AI-powered epitope selection algorithm, and strong, durable clinical immune responses, VB10.NEO is well-positioned to leverage on peer data readouts expected within the next 15 months.

Nykode will also continue investing in its ASIT platform to substantiate the platform's potential and explore partnerships to advance development and diversify indications.

Nykode will continue disciplined execution and financial focus to reach key inflection points within the estimated cash runway into 2028, with further extension into 2029 based on a positive outcome of the pending tax case.

QUARTERLY REPORT Q4 2025 Nykode Therapeutics9

CONDENSED CONSOLIDATED INTERIM STATEMENT OF COMPREHENSIVE INCOME

Nykode Therapeutics ASA | Gaustadalléen 21, N-0349 Oslo, Norway | W: nykode.com | Org.no. N-990 646 066 MVA

QUARTERLY REPORT Q4 2025 Nykode Therapeutics10

CONDENSED CONSOLIDATED INTERIM STATEMENT OF FINANCIAL POSITION

Chair of the Board

Board Member Board Member Board Member Board Member

CEO

Nykode Therapeutics ASA | Gaustadalléen 21, N-0349 Oslo, Norway | W: nykode.com | Org.no. N-990 646 066 MVA

QUARTERLY REPORT Q4 2025 Nykode Therapeutics11

CONDENSED CONSOLIDATED INTERIM STATEMENT OF CASH FLOWS

Nykode Therapeutics ASA | Gaustadalléen 21, N-0349 Oslo, Norway | W: nykode.com | Org.no. N-990 646 066 MVA

QUARTERLY REPORT Q4 2025 Nykode Therapeutics12

CONDENSED CONSOLIDATED INTERIM STATEMENT OF CHANGES IN EQUITY

Nykode Therapeutics ASA | Gaustadalléen 21, N-0349 Oslo, Norway | W: nykode.com | Org.no. N-990 646 066 MVA

‌NOTES TO THE INTERIM FINANCIAL STATEMENTS

1. General Information

   The condensed consolidated interim financial statements of Nykode Therapeutics ASA and its subsidiaries ("Nykode" or "the Group") for the period ended December 31, 2025 were authorized by the Board of Directors on February 24, 2026. Nykode's shares are traded on the Oslo Stock Exchange, with the ticker symbol NYKD. Nykode Therapeutics ASA is incorporated and domiciled in Norway, and the address of its registered office is Gaustadalléen 21, 0349 Oslo, Norway.

   The Group consists of clinical-stage biopharmaceutical companies, dedicated to the discovery and development of novel immunotherapies with a focus on the treatment of cancer and autoimmune diseases. Nykode's modular immunotherapy technology specifically targets antigens to Antigen Presenting Cells (APCs), which have been shown to induce broad, strong and long-lasting antigen specific immune response in cancer, which correlates with clinical responses. Nykode's lead product candidates are abi-suva, a therapeutic immunotherapy for the treatment of human papilloma virus 16 induced malignancies which demonstrated positive efficacy and safety results from its Phase 2 trial for the treatment of late-line r/m cervical cancer. Abi-suva is currently being further developed in head and neck cancer.

   VB10.NEO, an individualized cancer neoantigen immunotherapy, has been investigated two trials with more than 10 different indications. The Group is also utilizing its APC-targeted technology to create an immune tolerance platform for the potential use in autoimmune disorders, organ transplant rejections, anti-drug antibody reactions and allergy.

2. Basis of preparation and significant accounting policies

   The condensed consolidated interim financial statements of the Group comprise statement of comprehensive income, statement of financial position, statement of cash flows, statement of changes in equity and selected explanatory notes. The interim financial statements have been prepared in accordance with IAS 34 Interim Financial Reporting as adopted by the European Union ("EU"). The condensed consolidated interim financial statements are unaudited.

   The condensed consolidated interim financial statements do not include all the information and disclosures required in the annual financial statements and should be read in conjunction with Nykode's annual financial statements as at December 31, 2024. The accounting policies adopted in the preparation of the condensed consolidated interim financial statements are consistent with those followed in the preparation of Nykode's annual financial statements for the year ended December 31, 2024. The Group has not early adopted any standard, interpretation or amendment that has been issued but is not yet effective.

   The condensed consolidated interim financial statements have been prepared on a historical cost basis, except for financial instruments measured at fair value. The interim financial statements are presented in United States dollar (USD) which is also the functional currency of the parent company. Amounts are reported in whole thousands (USD '000) except when otherwise stated. Further, the interim financial statements are prepared based on the going concern assumption.

   Revenue from contracts with customers	Q4 2025	Q4 2024	YTD 2025	YTD 2024
   Major products and services R&D services	-	6,773	-	8,679
   Total revenue	-	6,773	-	8,679
   Geographical distribution	Q4 2025	Q4 2024	YTD 2025	YTD 2024

3. Material accounting judgements, estimates and assumptions

   The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances. Actual results may differ from these estimates. The estimates and the underlying assumptions are reviewed on an ongoing basis.

   In preparing the condensed consolidated interim financial statements, the material judgments, estimates and assumptions made by management in applying the Group's accounting policies and the key source of estimation uncertainty were the same as those applied to Nykode's annual financial statements for the year ended December 31, 2024

4. Operating segment and Revenue from contracts with customers

   The Group is organized as one operating segment.

   In the table below non-current assets are broken down by geographical areas based on the location of the operations:

   United States of America	-	6,773	-	8,679
   Total revenue	-	6,773	-	8,679

   The revenue information above is based on the location of the customers.

   Timing of revenue recognition Q4 2025 Q4 2024 YTD 2025 YTD 2024

   Goods/services transferred at a point in time Services transferred over time	- -	12 6,761	- -	226 8,453
   Total revenue	-	6,773	-	8,679

   The transaction price allocated to the remaining performance obligations (unsatisfied or partially unsatisfied) as at December 31, are as follows:

   Non-current assets 31/12/2025 31/12/2024

   Norway Denmark	37,578 486	35,726 689
   Total non-current assets	38,064	36,415

   Revenue from contracts with customers

   Revenue from contracts with customers relates to Nykode's delivery of R&D activities to Genentech and Regeneron under the respective agreements.

   Following the termination of the agreement with Genentech in November 2024, Nykode recognized the remaining contract liability as revenue in the fourth quarter of 2024.

   2025 2024

   Within one year More than one year	- -	- -
   Total	-	-

   Following the termination of the agreement with Genentech in the fourth quarter of 2024, Nykode no longer has any performance obligations.

   At 1 January Transferred to trade receivables Rendering of services in the period	- - -	(8,233) (220) 8,453
   Total contract assets/liabilities (-)	-	-

   Contract assets/liabilities (-) 31/12/2025 31/12/2024
5. Government grants Grant from SkatteFUNN

   The Group has one active R&D project approved by SkatteFUNN (a Norwegian government R&D tax incentive program designed to stimulate R&D in Norwegian trade and industry). The Group has recognized USD 0.0 million in the fourth quarter of 2025 (Q4 2024: USD 0.1 million) and USD 0.5 million in the full year 2025 (YTD 2024: USD 0.4 million) classified as other income.

   The Group had government grant receivables related to SkatteFUNN of USD 0.5 million at December 31, 2025 and USD 0.4 million as at December 31, 2024.

6. Other operating expenses

   Other operating expenses consisted mainly of research and development expenses in the fourth quarters of 2025 and 2024. Total research and development expenses were USD 3.8 million in the forth quarter of 2025 (Q4 2024: USD 9.1 million), and USD 13.4 million in the twelve months ended December 31, 2025. (Twelve months ended December, 31 2024: USD 39.7 million), recognized as employee benefit expenses, other operating expenses and depreciation in the statement of comprehensive income.

7. Financial income and costs Finance income Q4 2025 Q4 2024 YTD 2025 YTD 2024

   Gain on foreign exchange Interest income	50 607	1,050 1,337	9,733 3,554	1,998 7,002
   Total finance income	657	2,387	13,287	9,000

   Finance costs Q4 2025 Q4 2024 YTD 2025 YTD 2024

   Loss on foreign exchange Interest expenses Interest expense on lease liabilities	584 3 26	3,343 4 38	2,271 6 119	5,994 9 179
   Total finance costs	613	3,385	2,396	6,182

8. Unrecognised Deferred Tax Assets

   As per December 31, 2025, the Group's tax loss carried forward and other deductible temporary differences correspond to a potential deferred tax asset of USD 1.2 million. In accordance with IAS 12, no deferred tax asset has been recognized in the statement of financial position.

9. Shareholder Information 10 Financial instruments

Set out below is an overview of financial assets and liabilities held by the Group as at December 31, 2025 and December 31, 2024:

State Street Bank and Trust Comp 17,038,219 5.22 %

Portia AS 4,500,000 1.38 %

Krag Invest AS 4,470,100 1.37 %

Clearstream Banking S.A. 3,554,298 1.09 %

Verdipapirfondet KLP Aksjenorge IN 2,783,251 0.85 %

Alden AS 2,550,000 0.78 %

Other non-current receivables 28,601 - 28,601

Other receivables 1,668 - 1,668

Other current financial assets

There are no changes in the classification and measurement of the Group's financial assets and liabilities.

1. Share based payments

   The following tables illustrates the number and weighted average exercise price (WAEP) of, a re options during the periods:

   2025 2025 WAEP (NOK) Number

   Outstanding options at January 1	27.40	12,354,431
   Options granted	7.00	14,035,000
   Options forfeited	20.04	(2,647,708)

2. Events after the reporting date

Dr. Barbara Krebs-Pohl was elected Chair of the Board, and Dr. John Beadle and Susanne Stuffers were elected as Board members at an extraordinary general meeting held on January 21, 2026.

On January 30, 2026 a total of 600,000 share options were granted to these board members under the company's share option scheme and in accordance with the resolution from the extraordinary general meeting held on January 21, 2026. The share options have a strike price of NOK 7.00 per share. The share options will vest equally over a three year vesting period; on the date of the Annual General Meeting in 2027, the date of the Annual General Meeting in

‌Nykode Therapeutics ASA Gaustadalléen 21

0349 Oslo Norway

Phone: +47 22 95 81 93

E-mail: info@nykode.com

Organization number: N-990 646 066 MVA nykode.com

Nykode Therapeutics ASA | Gaustadalléen 21, N-0349 Oslo, Norway | W: nykode.com | Org.no. N-990 646 066 MVA